HIV Infections Clinical Trial
Official title:
KSHV Seroprevalence in Hospital Patients From San Antonio
To determine the seroprevalence of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8) in blood donors from Texas. Also to examine the donors' demographic characteristics and to characterize the KSHV using polymerase chain reaction.
BACKGROUND:
Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8) is a blood-borne virus that is
etiologically associated with Kaposi's sarcoma (KS), primary effusion lymphoma which is a
form of non-Hodgkin's lymphoma, and a subset of multicentric Castleman's disease which is a
lymphoproliferative disorder. The investigators developed serologic assays to measure
antibodies specific to KSHV latent and lytic antigens. Antibodies to KSHV antigens are found
in 70-100 percent of all clinical forms of KS patients. In contrast, relatively low
prevalence (2 to 5 percent) is found in the general population of North America.
Seroconversion is detected prior to KS onset in AIDS-KS patients, suggesting that primary
KSHV infection occurs predominantly in adulthood and is not ubiquitous. Antibody titers to
KSHV antigens remain elevated for years after seroconversion. The investigators have
recently found a 5 percent prevalence of KSHV infection in blood donors from San Antonio.
Further, KSHV has been found in the peripheral blood mononuclear cells (PBMC) of blood
donors, and organ transplantation and animal studies have provided evidence of likely
person-to-person transmission of KSHV. Thus, KSHV is a potential candidate for screening in
blood and plasma donors in view of its etiologic role for several malignancies, low but
appreciable prevalence in the general population, and lifelong persistence in a
cross-sectional study in blood donors from Texas.
DESIGN NARRATIVE:
The first aim of the study was to determine the prevalence of KSHV infection in blood donors
using specific KSHV serologic assays. The investigators used recently developed KSHV
specific serologic assays for detecting antibody to KSHV latent nuclear antigen, lytic
antigen, and orf65 (lytic antigen minor capsid protein) to determine the prevalence of KSHV
infection in a cross-sectional study of four representative blood banks in San Antonio,
Dallas, and Houston, Texas. A total of 500 random donors at each site were studied to detect
site-specific seroprevalence to plus or minus 2 percent with 95 percent confidence.
The second aim of the study was to analyze the demographic characteristics and the patterns
of other blood-borne infections of KSHV-seropositive blood donors. The cross-sectional study
in Houston and San Antonio was expanded to prospective study seroprevalence in a larger
population with questionnaire obtained demographic data to include gender, age, ethnicity,
education level, household income, and zip code. A total of 10,500 donors were obtained from
Houston. As the San Antonio center had the highest proportion of Hispanic donors, an
additional 2,000 donors were obtained and characterized demographically.
The third aim was to investigate KSHV molecular epidemiology in blood donors through
sequence determination of specific nested-polymerase chain reaction (PCR) and RT-PCR
products from peripheral blood mononuclear cells (PBMC) of KSHV-seropositive donors. The
2,000 blood samples from San Antonio were also used to amplify KSHV sequences from
peripheral blood mononuclear cells of KSHV positive donors using PCR, nested PCR and RT-PCR
with and without phorbol ester induction. Sequencing of amplified products was compared to
KSHV isolates from New York, Italy, England, and Africa for phylogenetic analysis and
assessment of diversity and distribution of KSHV strains in Texas. While the proposed
sampling represented only one center in Texas, comparison to isolates for New York and
abroad allowed determination of the likelihood that Texas strains were unique or imported
from Europe or Africa.
This regional project was performed in collaboration with the University Health System Donor
Center in San Antonio, BloodCare in Dallas, and Gulf Coast Regional Blood Center in Houston,
thus providing results for three separate metropolitan areas with rather different ethnic
compositions. These studies should provide valuable information to assess the necessity and
feasibility of national screening of blood donors for KSHV, and gain insight into the
patterns of infection as well as the diversity, the distribution, and the origins of the
virus strains in blood donors.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |